Rabies and meningities vaccine producer Kanghua Biological, which counts Aokang and Tigermed as investors, has floated in its home country of China.
Kanghua Biological, a China-based vaccine provider backed by clinical services provider Tigermed and leather product supplier Aokang, raised almost RM1.06bn ($149m) in its initial public offering, DealStreetAsia has reported.
The offering consisted of 15 million shares issued on the Shenzhen Stock Exchange’s ChiNext board and priced at RMB70.37 each. Minsheng Securities is the lead underwriter for the IPO.
Founded in 2004 by Aokang chairman Wang Zhentao, Kanghua produces vaccines for rabies and meningitis, and has an influenza vaccine in development…
